Highlights From Post-ASCO Breast Cancer KOL Call

Research evidence excerpt

Highlights From Post-ASCO Breast Cancer KOL Call

TD SECURITIES (USA) LLC CONFERENCE CALL

June 11, 2026

■Biotechnology Highlights From Post-ASCO Breast Cancer

KOL Call

TD Cowen Biotechnology Team THE TD COWEN INSIGHT

646 562 1010

Our KOL was impressed by CELC's V-1 MT data and believed full coverage of the 2L would lead

biotechteam@tdsecurities.com

to prescribing based on disease severity instead of mutational status, envisioning 50-60% as

TD Cowen Pharmaceutical Team potential geda candidates. He was also bullish on RLAY's zovega, which he thinks will succeed

617 946 3923 in Ph3 with ~12 mos mPFS and capture majority share in 2L+ PIK3CA MTs. SERDs, KAT6, CDK4,

pharmateam@tdsecurities.com

and TROP2 also discussed.

Tara Bancroft, Ph.D.

646 562 1410 We hosted a breast cancer KOL for an investor webcast following ASCO 2026, during which

tara.bancroft@tdsecurities.com we discussed programs from a number of companies under coverage including CELC, RLAY,

Tyler Van Buren ONC, OLMA, GILD, LLY, RHHBY, and AZN.

646 562 1343

Key takeaways are listed below and fleshed out in greater detail in the PDF.

tyler.vanburen@tdsecurities.com

■KOL Was Impressed With VIKTORIA-1 MT Data At ASCO And Believed It Would Be

Yaron Werber, M.D. "Practice Changing" For Many Patients

646 562 1415

yaron.werber@tdsecurities.com ■The Similar Doublet Performance Could Be Due To Sample Size Differences Or Use Of

Weaker CDK4/6 In Triplet

Michael Nedelcovych, Ph.D.

617 946 3744 ■Geda's AE Profile Is Surprisingly, But Distinctly, Improved vs. The Class

michael.nedelcovych@tdsecurities.com

■KOL Expects Up To 60% Of 2L PIK3CA-MT Patients Will Be Candidates For Geda, While

The Rest Could Eventually Receive It In The 3L

■The Triplet May Be Best For Patients With Reduced CDK4/6 Exposure In 1L Or With Higher